<DOC>
	<DOC>NCT00494299</DOC>
	<brief_summary>Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.</brief_summary>
	<brief_title>Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male or female Aged of 18 and over Advanced hepatocellular carcinoma History of prior systemic chemotherapy Failure in vital organ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HCC</keyword>
	<keyword>Cancer</keyword>
	<keyword>Liver Cancer</keyword>
	<keyword>TACE</keyword>
</DOC>